Research Article
BibTex RIS Cite

MEME KANSERİ BİYOPSİ ve REZEKSİYON MATERYALLERİNDE HORMON RESEPTÖRLERİ (ER/PgR) ve HER2 DEĞERLERİNİN KARŞILAŞTIRILMASI

Year 2020, Volume: 27 Issue: 2, 154 - 159, 01.06.2020
https://doi.org/10.17343/sdutfd.598845

Abstract

Amaç:
Meme kanseri tanısı almış olgularda, biyopsi
ve rezeksiyon materyalleri arasındaki uyumun değerlendirilmesi ve tümör alt
tipleri, östrojen reseptörü (ER),
progesteron reseptörü (PgR) ve HER2 düzeylerine göre patolojik
durumlarının karşılaştırılması ve sonuçların literatür eşliğinde irdelenmesi amaçlanmıştır.



Gereç ve Yöntem: Kırıkkale Üniversitesi Tıp Fakültesi
Tıbbi Patoloji Ana Bilim Dalı’nda Ocak 2013 ve Haziran 2019 tarihleri arasında
malign tanı almış, meme biyopsi ve rezeksiyon materyalleri bulunan hastalara
ait patoloji raporları incelendi. Her iki materyali de bölümümüzde bulunan 14 olgunun, hemotoksilen-eozin ve
immünhistokimyasal ER, PgR ve HER2 preparatları arşivden çıkarılarak tekrar
değerlendirildi. Sonuçlar arasındaki tutarlılıklar hesaplandı.



Bulgular:
Meme karsinomu tanısı alan olguların
biyopsi ve rezeksiyon materyalleri arasındaki tümör derece uyumu % 78,5 olarak saptandı. Her iki materyal arasında
skor tutarlılıkları ER ile % 100, PgR ile %92,8, HER2 % 78,5 olarak belirlendi. Moleküler alt tiplerdeki
uyum ise % 88,9 olarak saptandı.



Sonuç: Çalışmamız kapsamındaki meme karsinomu vakalarına
ait biyopsi ve rezeksiyon materyalleri arasında; tümör derecesi, ER/PgR
ekspresyonu, HER2 skorları ve moleküler alt tipler bakımından yüksek
oranda tutarlılık saptandı. Söz konusu yüksek tutarlılık oranına rağmen,
tümörün tamamını temsil etme özelliğine sahip rezeksiyon materyallerinin, tedavi ve prognozda önemli bilgiler veren ER/PgR
ve HER2 skorları bakımından değerlendirmelerinin hasta yönetimindeki başarıyı arttıracağı sonucuna varılmıştır. 

References

  • 1. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the World. Breast Cancer (Dove Med Press). 2019;11:151-164.
  • 2. Ferley J, SoerjomataramI I, Ervik M, Dikshit R, Eser S. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
  • 3. Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J. WHO Classification of Tumours of the Breast. 4th Edition. WHO Classification of Tumours, No 4. IARC. ISBN-13 9789283224334. 2012
  • 4. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. ABREAST Investigators The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005;6(5):391-401.
  • 5. Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol 2019;30(5):781-787.
  • 6. Davidson TM, Rendi MH, Frederick PD, Onega T, Allison KH, Mercan E, Brunyé TT, Shapiro LG, Weaver DL, Elmore JG. Breast cancer prognostic factors in the digital era: comparison of nottingham grade using whole slide ımages and glass slides. J Pathol Inform. 2019,3;10:11.
  • 7. Tang P., Bui M.M., Peng Y. Immunohistochemistry in Breast Cancer. Practical Breast Pathology. Practical Anatomic Pathology. First ed. Springer, Cham,173-192, 2019.
  • 8. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2013;24:2206-23.
  • 9. Gulzar R, Shahid R, Saleem O. Molecular subtypes of breast cancer by immunohistochemical profiling. Int J Pathol 2018;16(2):129-134.
  • 10. Wunderle M, Pretscher J, Brucker SY, et al. Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Res Treat 2019;174:453-61
  • 11. Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J. et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130(3):609-14.
  • 12. Brown M1, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008;112(4):737-47.
  • 13. Ateş C, Öztuna D, Genç Y. Sağlık araştırmalarında sınıf içi korelasyon katsayısının kullanımı. Turkiye Klinikleri J Biostat 2009;1(2):59-64.
  • 14. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
  • 15. Alkabban FM, Ferguson T. Cancer, Breast. StatPearls Publishing Treasure Island (FL). 2019.
  • 16. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014; 5: 412-424.
  • 17. Kunc M, Biernat W, Senkus-Konefka E. Estrogen receptor-negative progesterone receptor-positive breast cancer-"Nobody's land" or just an artifact? Cancer Treat Rev 2018;67:78-87.
  • 18. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul;134(7):e48-72.
  • 19. Liedtke C1, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20(12):1953-8.
  • 20. Zhu S, Wu J, Huang O, He J, Zhu L, Li Y, Chen W, Fei X, Chen X, Shen K. Clinicopathological features and disease outcome in breast cancer patients with hormonal receptor discordance between core needle biopsy and following surgical sample. Ann Surg Oncol 2019 doi: 10.1245/s10434-019-07480-y.
  • 21. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012;2012:743193.
  • 22. Kondov B, Milenkovikj Z, Kondov G, et al. Presentation of the molecular subtypes of breast cancer detected by ımmunohistochemistry in surgically treated patients. Open Access Maced J Med Sci. 2018;6(6):961-967.
  • 23. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7(1-2):4-13.
Year 2020, Volume: 27 Issue: 2, 154 - 159, 01.06.2020
https://doi.org/10.17343/sdutfd.598845

Abstract

References

  • 1. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the World. Breast Cancer (Dove Med Press). 2019;11:151-164.
  • 2. Ferley J, SoerjomataramI I, Ervik M, Dikshit R, Eser S. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
  • 3. Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J. WHO Classification of Tumours of the Breast. 4th Edition. WHO Classification of Tumours, No 4. IARC. ISBN-13 9789283224334. 2012
  • 4. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. ABREAST Investigators The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005;6(5):391-401.
  • 5. Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol 2019;30(5):781-787.
  • 6. Davidson TM, Rendi MH, Frederick PD, Onega T, Allison KH, Mercan E, Brunyé TT, Shapiro LG, Weaver DL, Elmore JG. Breast cancer prognostic factors in the digital era: comparison of nottingham grade using whole slide ımages and glass slides. J Pathol Inform. 2019,3;10:11.
  • 7. Tang P., Bui M.M., Peng Y. Immunohistochemistry in Breast Cancer. Practical Breast Pathology. Practical Anatomic Pathology. First ed. Springer, Cham,173-192, 2019.
  • 8. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2013;24:2206-23.
  • 9. Gulzar R, Shahid R, Saleem O. Molecular subtypes of breast cancer by immunohistochemical profiling. Int J Pathol 2018;16(2):129-134.
  • 10. Wunderle M, Pretscher J, Brucker SY, et al. Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Res Treat 2019;174:453-61
  • 11. Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J. et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130(3):609-14.
  • 12. Brown M1, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008;112(4):737-47.
  • 13. Ateş C, Öztuna D, Genç Y. Sağlık araştırmalarında sınıf içi korelasyon katsayısının kullanımı. Turkiye Klinikleri J Biostat 2009;1(2):59-64.
  • 14. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
  • 15. Alkabban FM, Ferguson T. Cancer, Breast. StatPearls Publishing Treasure Island (FL). 2019.
  • 16. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014; 5: 412-424.
  • 17. Kunc M, Biernat W, Senkus-Konefka E. Estrogen receptor-negative progesterone receptor-positive breast cancer-"Nobody's land" or just an artifact? Cancer Treat Rev 2018;67:78-87.
  • 18. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul;134(7):e48-72.
  • 19. Liedtke C1, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20(12):1953-8.
  • 20. Zhu S, Wu J, Huang O, He J, Zhu L, Li Y, Chen W, Fei X, Chen X, Shen K. Clinicopathological features and disease outcome in breast cancer patients with hormonal receptor discordance between core needle biopsy and following surgical sample. Ann Surg Oncol 2019 doi: 10.1245/s10434-019-07480-y.
  • 21. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012;2012:743193.
  • 22. Kondov B, Milenkovikj Z, Kondov G, et al. Presentation of the molecular subtypes of breast cancer detected by ımmunohistochemistry in surgically treated patients. Open Access Maced J Med Sci. 2018;6(6):961-967.
  • 23. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7(1-2):4-13.
There are 23 citations in total.

Details

Primary Language Turkish
Subjects Surgery
Journal Section Research Articles
Authors

Tuba Devrim 0000-0002-5321-2002

Merva Aydemir

Publication Date June 1, 2020
Submission Date July 30, 2019
Acceptance Date August 22, 2019
Published in Issue Year 2020 Volume: 27 Issue: 2

Cite

Vancouver Devrim T, Aydemir M. MEME KANSERİ BİYOPSİ ve REZEKSİYON MATERYALLERİNDE HORMON RESEPTÖRLERİ (ER/PgR) ve HER2 DEĞERLERİNİN KARŞILAŞTIRILMASI. Med J SDU. 2020;27(2):154-9.

                                                                                               14791 


Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi/Medical Journal of Süleyman Demirel University is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International.